Table 1 Main characteristics of the studies examining the relationship between circulating leptin, adiponectin levels and HCC
Author, Year, Country | Study design | Study period | the source of case group | the source of Cancer-free control group | Number | Mean age | Males | BMI | Sample source | Measured indicators | Detected method | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abouzied, 2017, Egypt | C | – | HCC | Healthy controls | 25/25 | 57.7/29.2 | 18/23 | 21.7/22.2 | Serum | Leptin | ELISA | 5 |
Aleksandrova, 2014, Europe | N | 2000–2006 | HCC | Healthy controls | 125/250 | 60.1/60.1 | 85/171 | 28.1/26.9 | Serum | Leptin and AdipoQ | ELISA | 8 |
Ataseven, 2006, Yurkey | C | – | HBV-related HCC | HBV-related cirrhosis/ Healthy controls | 22/23/25 | 59.8/45.5/37.1 | 15/11/11 | – | Serum | Leptin | ELISA | 8 |
Bakir, 2017, Egypt | S | 03/2016–11/2016 | HCV-related cirrhotic HCC | HCV-related cirrhosis | 50/40 | 53.2/50.7 | 29/25 | 24.5/26.1 | Serum | Leptin | ELISA | 5 |
Bastard, 2018, France | N | 03/2006–07/2016 | Viral cirrhotic HCC | Viral cirrhosis | 56/96 | 59.8/58.9 | 34/61 | 25.6/25.8 | Serum | Leptin and AdipoQ | ELISA | 7 |
Chen, CL, 2014, Taiwan | N | 01/1999–12/2004 | HBV-related HCC | Chronic hepatitis B | 187/374 | 52.4/52.2 | 154/311 | – | Plasma | Leptin and AdipoQ | ELISA | 8 |
Chen, MJ, 2012, Taiwan | C | 01/2009–12/2009 | Viral HCC | Healthy controls | 65/165 | 58.8/47.7 | 47/112 | 24.7/24.4 | Serum | AdipoQ | RIA | 6 |
Costantini,2013, Italy | C | – | HCV-related HCC | HCV-related cirrhosis / Chronic hepatitis C / Healthy controls | 26/30/30/20 | 70.0/68/63.4/60.9 | 18/14/15/9 | – | Serum | Leptin | ELISA | 8 |
Feder, 2019, Germany | P | 05/2012–05/2015 | HCC | Healthy controls | 32/49 | – | – | – | Serum | AdipoQ | ELISA | 7 |
Fukushima, 2010, Japan | P | 1993–2003 | HCV-related HCC | Chronic hepatitis C | 9/27 | 53.0/51.3 | 5/11 | – | Serum | Leptin (RIA) and HMW AdipoQ (ELISA) | 8 | |
Hamdy, 2015, Egypt | S | 01/2014–12/2014 | HCV-related cirrhotic HCC | HCV-related cirrhosis | 61/29 | 52.3/52.3 | 51/21 | 33.7/36.7 | Serum | AdipoQ | ELISA | 8 |
Khattab, 2012, Egypt | C | 02/2009–01/2010 | HCC | Chronic hepatitis C / Healthy controls | 147/147/320 | 43.9/41.6/42.9 | 114/115/201 | 24.9/25.1/25.3 | Serum | AdipoQ | ECLI | 6 |
Kotani, 2009, Japan | N | 1990–1999 | HCC | Healthy controls | 59/334 | 63.5/62.7 | – | – | Serum | AdipoQ | ELISA | 5 |
Liu, CJ, 2009, Taiwan | S | 01/2002–10/2005 | HBV-related HCC | HBV-related cirrhosis / Chronic hepatitis B/ Healthy controls | 120/40/120/116 | 50.7/50.3/30/53.8 | 100/29/63/67 | – | Serum | AdipoQ | ELISA | 8 |
Liu, ZW, 2005, China | C | – | HCV-related cirrhotic HCC | HCV-related cirrhosis/ Chronic hepatitis C/ Healthy controls | 2/10/30/30 | 59.5/53.7/41/39.4 | 2/6/17/18 | 23.0/22.7/23.0/23.1 | Serum | Leptin | ELISA | 8 |
Michikawa, 2013, Japan | N | 1993–2006 | Viral HCC | Chronic viral hepatitis | 90/117 | – | 62/80 | – | plasma | AdipoQ | ELISA | 8 |
Radwan, 2019, Egypt | S | – | HCC | Chronic hepatitis C | 48/52 | 53.2/52.5 | 26/32 | 25.2/27.7 | Serum | AdipoQ | ELISA | 5 |
Sadik, 2012, Egypt | C | 01/2008–02/2009 | HCV-related HCC | HCV-related cirrhosis/ Healthy controls | 69/36/21 | 59.1/53.0/55.8 | 43/23/13 | 28.0//27.1/29.1 | Serum | Leptin and AdipoQ | ELISA | 6 |
Sumie, 2011, Japan | C | 01/1997–10/2007 | HCV-related HCC | Chronic hepatitis C | 97/97 | 67.4/61.2 | 67/67 | 22.5/23.1 | Serum | AdipoQ | ELISA | 7 |
Voumvouraki, 2011, Greece | C | – | Viral cirrhotic HCC | Viral cirrhosis/ Chronic hepatitis C / Healthy controls | 38/34/44/60 | 62.0/60.0/53.0/−− | 25/12/8/−− | – | Serum | Leptin | ELISA | 8 |
Wang, 2003, Taiwan | C | 01/2000–12/2000 | Viral cirrhotic HCC | Viral cirrhosis/ Healthy controls | 31/26/25 | 65.0/59.0/65.0 | 31/26/25 | 23.2/23.7/24.4 | Serum | Leptin | RIA | 6 |